Modulation of recombinant human cardiac L-type Ca2+ channel α1C subunits by redox agents and hypoxia

被引:113
作者
Fearon, IM
Palmer, ACV
Balmforth, AJ
Ball, SG
Varadi, G
Peers, C [1 ]
机构
[1] Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England
[2] Univ Cincinnati, Coll Med, Inst Mol Pharmacol & Biophys, Cincinnati, OH 45267 USA
来源
JOURNAL OF PHYSIOLOGY-LONDON | 1999年 / 514卷 / 03期
关键词
D O I
10.1111/j.1469-7793.1999.629ad.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
1. Whole-cell patch clamp recordings were used to investigate the modulation by reducing and oxidizing agents of recombinant human cardiac L-type Ca2+ channel alpha(1C) subunits stably expressed in human embryonic kidney (HEK 293) cells. 2. The oxidizing agents thimerosal (10 mu M) and p-chloromercuribenzene sulphonic acid (PCMBS; 2 mu M to 2 mM) caused irreversible inhibition of Ca2+ channel currents. The reducing agent 1,4-dithiothreitol (DTT; 2 mM) was without effect on Ca2+ channel currents, but reversed the inhibitory actions of thimerosal and PCMBS. 3. Ca2+ channel currents were also inhibited by pretreatment with the methanethiosulphonate compound (2-aminoethyl)methanethiosulphonate (MTSEA, 2.5 mM), but were unaffected by identical pretreatment with (2-sulphonatoethyl)methanethiosulphonate (MTSES, 10 mM). The effects of MTSEA could be fully reversed by DTT (2 mM). The degree of current inhibition caused by 200 mu m PCMBS was not significantly affected by pretreatment with MTSEA, and following PCMBS treatment, MTSEA caused a similar degree of inhibition to that observed in cells that were not previously treated with PCMBS. These findings suggested that distinct thiol groups were modulated by these two agents. 4. Hypoxic inhibition of Ca2+ channel currents was unaffected by pretreatment of cells with MTSEA but was fully prevented by treatment with PCMBS. Our results indicate that distinct cysteine residues on the ct,, subunit can undergo redox modulation and in so doing alter channel function. Some, but not all, of these residues appear to be associated with the mechanism underlying inhibition of this channel by hypoxia.
引用
收藏
页码:629 / 637
页数:9
相关论文
共 31 条
  • [1] ACKER H, 1995, NEWS PHYSIOL SCI, V10, P211
  • [2] THE MEANING OF H2O2 GENERATION IN CAROTID-BODY CELLS FOR PO2 CHEMORECEPTION
    ACKER, H
    BOLLING, B
    DELPIANO, MA
    DUFAU, E
    GORLACH, A
    HOLTERMANN, G
    [J]. JOURNAL OF THE AUTONOMIC NERVOUS SYSTEM, 1992, 41 (1-2): : 41 - 52
  • [3] ACETYLCHOLINE-RECEPTOR CHANNEL STRUCTURE PROBED IN CYSTEINE-SUBSTITUTION MUTANTS
    AKABAS, MH
    STAUFFER, DA
    XU, M
    KARLIN, A
    [J]. SCIENCE, 1992, 258 (5080) : 307 - 310
  • [4] MYOCARDIAL CONTRACTILE FUNCTION DURING ISCHEMIA AND HYPOXIA
    ALLEN, DG
    ORCHARD, CH
    [J]. CIRCULATION RESEARCH, 1987, 60 (02) : 153 - 168
  • [5] A REDOX-BASED O2 SENSOR IN RAT PULMONARY VASCULATURE
    ARCHER, SL
    HUANG, J
    HENRY, T
    PETERSON, D
    WEIR, EK
    [J]. CIRCULATION RESEARCH, 1993, 73 (06) : 1100 - 1112
  • [6] Benndorf K, 1997, NEWS PHYSIOL SCI, V12, P78
  • [7] Redox modulation of L-type calcium channels in ferret ventricular myocytes - Dual mechanism regulation by nitric oxide and S-nitrosothiols
    Campbell, DL
    Stamler, JS
    Strauss, HC
    [J]. JOURNAL OF GENERAL PHYSIOLOGY, 1996, 108 (04) : 277 - 293
  • [8] FUNCTIONAL CONSEQUENCES OF SULFHYDRYL MODIFICATION IN THE PORE-FORMING SUBUNITS OF CARDIOVASCULAR CA2+ AND NA+ CHANNELS
    CHIAMVIMONVAT, N
    OROURKE, B
    KAMP, TJ
    KALLEN, RG
    HOFMANN, F
    FLOCKERZI, V
    MARBAN, E
    [J]. CIRCULATION RESEARCH, 1995, 76 (03) : 325 - 334
  • [9] Hypoxia inhibits the recombinant alpha(1C) subunit of the human cardiac L-type Ca2+ channel
    Fearon, IM
    Palmer, ACV
    Balmforth, AJ
    Ball, SG
    Mikala, G
    Schwartz, A
    Peers, C
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1997, 500 (03): : 551 - 556
  • [10] Inhibition of recombinant human cardiac L-type Ca2+ channel α1C subunits by 3-isobutyl-1-methylxanthine
    Fearon, IM
    Palmer, ACV
    Balmforth, AJ
    Ball, SG
    Mikala, G
    Peers, C
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 342 (2-3) : 353 - 358